Peijing Yan

Peijing Yan

Auto-generated profile, based on publicly available information

Peijing Yan

Clinical Research Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2019 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
LCLiujiao Cao
Liujiao Cao
XLXiuxia Li
Xiuxia Li
PYPeijing Yan
Peijing Yan
XWXiaoqin Wang
Xiaoqin Wang
MLMeixuan Li
Meixuan Li
KYKehu Yang
Kehu Yang
The study aims to evaluate the effectiveness of different durations of aerobic exercise on hypertensive patients. Four electronic databases (PubMed, Embase, Cochrane Library, and Web of Science) were searched from their inception until July 2018. English publications and randomized controlled trials involving aerobic exercise treatment for hypertensive population were included. Two reviewers independently extracted the data. The Cochrane's Risk of Bias tool was used to assess the quality of included studies. In this systematic review, a total of 14 articles were included, involving 860 participants. The quality of the included studies ranged from moderate to high. The results of the meta‐analysis showed that compared with the control group, significant effects of aerobic exercise were observed on reducing systolic blood pressure (SBP) (mean difference [MD] = −12.26 mm Hg, 95% confidence interval [CI] = −15.17 to −9.34, P < 0.05), diastolic blood pressure (DBP; MD = −6.12 mm Hg, 95% CI = −7.76 to −4.48, P < 0.05), and heart rate (MD = −4.96 bpm, 95% CI = −6.46 to −3.43, P < 0.05). In addition, significant reductions were observed in ambulatory DBP (MD = −4.90 mm Hg, 95% CI = −8.55 to −1.25, P < 0.05) and ambulatory SBP (MD = −8.77mm Hg, 95% CI = −13.97 to −3.57, P < 0.05). Therefore, aerobic exercise might be an effective treatment for blood pressure improvement in hypertensive patients. However, the effectiveness between the duration of different treatment needs to be well‐designed and rigorous studies will be required to verify the dataset.

1 May 2019 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
PYPeijing Yan
Peijing Yan
LYLiang Yao
Liang Yao
HLHuijuan Li
Huijuan Li
MZMin Zhang
Min Zhang
YXYangqin Xun
Yangqin Xun
KYKehu Yang
Kehu Yang

1 April 2020 in Shock
Verified
Journal Article
Open access
QHQiangru Huang
Qiangru Huang
HXHuaiyu Xiong
Huaiyu Xiong
PYPeijing Yan
Peijing Yan
TSTiankui Shuai
Tiankui Shuai
JLJingjing Liu
Jingjing Liu
NGNa Guo
Na Guo
Background: Soluble urokinase-type plasminogen activator receptor (suPAR) has the potential to diagnose infectious diseases. Due to the lack of reliable biomarkers and the importance of timely diagnosis for sepsis treatment, we conducted this systematic review and meta-analysis to evaluate the value of suPAR diagnosis and prognosis for sepsis. Methods: PubMed, Embase, Web of Science, and Cochrane Library databases were searched for studies, which reported the value of suPAR diagnosis and/or prognosis in patients with sepsis. Results: A total of 30 studies involving 6,906 patients were included. Sensitivity and specificity of suPAR for diagnosing sepsis were 0.76 [95% confidence interval (CI), 0.63–0.86] and 0.78 (95% CI, 0.72–0.83), respectively. The area under the summary receiver-operating characteristic curve (AUC) was 0.83 (95% CI, 0.80–0.86). Pooled sensitivity and specificity for predicting mortality were 0.74 (95% CI, 0.67–0.80) and 0.70 (95% CI, 0.63–0.76), respectively, with AUC of 0.78 (95% CI, 0.74–0.82). In addition, AUC for differentiating sepsis from systemic inflammatory response syndrome (SIRS) was 0.81 (95% CI, 0.77–0.84), and the sensitivity and specificity were 0.67 (95% CI, 0.58–0.76) and 0.82 (95% CI, 0.73–0.88), respectively. Conclusion: suPAR is a feasible biomarker for timely diagnosis and prognosis of sepsis. Compared with effective value of procalcitonin (PCT) identified by previous meta-analysis, suPAR has similar clinical guiding value, whereas suPAR exhibits higher specificity, which can facilitate the deficiencies of PCT. suPAR also shows a diagnostic value in differentiating sepsis from SIRS. Considering the lack of biomarkers for sepsis and the similar clinical value of suPAR and PCT, suPAR should be considered as a biomarker in clinical practice for sepsis.

28 June 2018 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
CHCaiwen Han
Caiwen Han
XSXinyi Shan
Xinyi Shan
LYLiang Yao
Liang Yao
PYPeijing Yan
Peijing Yan
MLMeixuan Li
Meixuan Li
TGTiankang Guo
Tiankang Guo

1 June 2020 in Aging Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
YLYongfeng Lao
Yongfeng Lao
LHLijuan Hou
Lijuan Hou
JLJing Li
Jing Li
XHXu Hui
Xu Hui
PYPeijing Yan
Peijing Yan
KYKehu Yang
Kehu Yang

1 April 2019 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
MLMeixuan Li
Meixuan Li
XXXin Xing
Xin Xing
LYLiang Yao
Liang Yao
XLXiuxia Li
Xiuxia Li
WHWenbo He
Wenbo He
KYKehu Yang
Kehu Yang